> Chebrytė, judviems verta pasidomėti, kaip tie 95% suskaičiuojami.
> Garantuotai rasit neįtartų dalykų ;-)
>

Tai domėjausi iškart, kai tik rezultatus publikavo, pva Pfizer/Biontech:

https://www.nejm.org/doi/full/10.1056/nejmoa2034577
"A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions."

Atmetus visus patikimumo niuansus, paprasta aritmetika parodo galutinį rezultatą:
8 / 162 * 100 = 4.9382716049...%
užsikrėtė paskiepytųjų lyginant su placebo grupe, reiškia, apsaugojimo efektyvumas:
100 - 4.9382716049... = 95.06172839506..%

O čia užsikrėtimų kriterijai:

"Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as the presence of at least one of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by nucleic acid amplification–based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test)."